Exo4UL: Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation

Sponsor
University of Liverpool (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05615766
Collaborator
Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust (Other), The Queen Elizabeth National Spinal Injuries Unit, Scotland (Other), Stoke Mandeville Spinal Research (Other)
9
2
36

Study Details

Study Description

Brief Summary

Rehabilitation robotics has the potential to facilitate rehabilitation at home and empower people with spinal injuries to self-manage increasing their independence and improving their quality of life.

The objective of this study is to assess for the first time in the NHS the efficacy of a commercial robotic orthosis for upper limb rehabilitation in patients with spinal cord injury. The device is produced by Myomo (myomo.com) which is an American company. We will be assessing the wearable robotic orthosis also known as robotic exoskeleton in two different neuro-rehabilitation centres: National Spinal injuries Unit in Glasgow (Scotland) and The Robert Jones and Agnus Hunt Orthopaedic Hospital in Oswestry (England). The study will involve nine spinal cord injured tetraplegic inpatients in total.

Patients will follow a twelve-week rehabilitation programme with three to four sessions per week in addition to their usual care and rehabilitation. Each session lasts for approximately 45 minutes. Participants arm function, range of motion, spasticity level will be measured before, half-way and at the end of the programme to assess change in these and other parameters. Training will focus on the dominant arm of the patient and compared to the other arm at every assessment stage.

We shall evaluate therapists' and patients' satisfaction with the commercial device in addition to assessing various clinical measures to evaluate the efficacy of using the robotic orthosis in rehabilitation and recovery of arm function.

Condition or Disease Intervention/Treatment Phase
  • Device: Experimental: Device Intervention
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
9 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
Single (Investigator)
Primary Purpose:
Device Feasibility
Official Title:
EXO4UL- Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation of Spinal Cord Injured Patients
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Device Intervention

The intervention group who will be undergoing rehabilitation using the robotic exoskeleton in addition to the assigned traditional rehabilitation programme on their dominant arm only.

Device: Experimental: Device Intervention
The robotic rehabilitation programme using the MARK from Myomo (myomo.com) for the intervention group will last for 12 weeks with up to four sessions of rehabilitation per week, i.e. total of 48 sessions. Spinal cord injured inpatients in the study will have this intervention on their dominant arm in addition to the traditional rehabilitation programme assigned and standard care.
Other Names:
  • Robotic Rehabilitation
  • No Intervention: Control

    the matched control group will be the same subjects undergoing traditional rehabilitation only on their non-dominant arm.

    Outcome Measures

    Primary Outcome Measures

    1. Spinal Cord Independence Measure version III (SCIM III) [Change from baseline (week 1) at 6 weeks]

      assesses performance in activities of daily living and mobility for individuals with spinal cord injury

    2. Spinal Cord Independence Measure version III (SCIM III) [Change from baseline (week 1) at 12 weeks]

      assesses performance in activities of daily living and mobility for individuals with spinal cord injury

    Secondary Outcome Measures

    1. The Graded Redefined Assessment of Strength, Sensation and Prehension (GRASSP). [Change from baseline (week 1) at 6 weeks and 12 weeks]

      The GRASSP is a clinical impairment measure for the upper limb for use after tetraplegia. The measure includes three domains which are important in describing hand function.

    2. The modified Ashworth scale [Change from baseline (week 1) at 6 weeks and 12 weeks]

      Ashworth scale is the most universally accepted clinical spasticity assessment tool used to measure the increase of muscle tone.

    3. Range of Motion [Change from baseline (week 1) at 6 weeks and 12 weeks]

      to assess the capability of a joint to go through its complete spectrum of movements

    4. Canadian Occupational Performance Measure (COPM) [Change from baseline (week 1) at 6 weeks and 12 weeks]

      COPM assesses the patient's perceived occupational performance in the areas of selfcare, productivity, and leisure

    Other Outcome Measures

    1. The Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) [Change from baseline (week 1) at 6 weeks and 12 weeks]

      The QUEST 2.0 evaluates a patient's satisfaction with various assistive technologies.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 18+ years.

    • The levels of C5 C6 Asia C/D would provide individuals with elbow and hand impairment and potentially functional shoulder movements. C7, C8 individuals could also benefit from the hand component of the device.

    • Some gross shoulder movement at start of the trial to enable changes at the elbow/hand, to have the greatest potential for functional change.

    • Preservation of hand sensation as base for motor restoration.

    • Some sitting balance would give the best opportunity for the arm to be released for functional upper limb activity.

    • EMG (muscle activity) evidence of active finger flexion, extension and elbow flexion extension Grade 1-2.

    • Minimal or No community functional use of upper limb at start of trial.

    • Spasticity MAS 1-3/5.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Liverpool
    • Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
    • The Queen Elizabeth National Spinal Injuries Unit, Scotland
    • Stoke Mandeville Spinal Research

    Investigators

    • Principal Investigator: Heba Lakany, PhD, University of Liverpool
    • Study Director: Simon J Pickard, Robert Jones and Agnes Hunt Orthopaedic Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Heba Lakany, Principal Investigator, University of Liverpool
    ClinicalTrials.gov Identifier:
    NCT05615766
    Other Study ID Numbers:
    • IRAS312522
    First Posted:
    Nov 14, 2022
    Last Update Posted:
    Nov 14, 2022
    Last Verified:
    Nov 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 14, 2022